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Abstract
Background: Smartphone-based ecological momentary assessment and intervention (EMA/I) show promise for
enhancing psychological treatments for psychosis. EMA has the potential to improve assessment and formulation of
experiences which fluctuate day-to-day, and EMI may be used to prompt use of therapeutic strategies in daily life.
The current study is an examination of these capabilities in the context of a brief, coping-focused intervention for
distressing voice hearing experiences.
Methods/design: This is a rater-blinded, pilot randomised controlled trial comparing a four-session intervention in
conjunction with use of smartphone EMA/I between sessions, versus treatment-as-usual. The recruitment target is
34 participants with persisting and distressing voice hearing experiences, recruited through a Voices Clinic based in
Melbourne, Australia, and via wider advertising. Allocation will be made using minimisation procedure, balancing of
the frequency of voices between groups. Assessments are completed at baseline and 8 weeks post-baseline. The
primary outcomes of this trial will focus on feasibility and acceptability of the intervention and trial methodology,
with secondary outcomes examining preliminary clinical effects related to overall voice severity, the emotional and
functional impact of the voices, and emotional distress.
Discussion: This study offers a highly novel examination of specific smartphone capabilities and their integration
with traditional psychological treatment for distressing voices. Such technology has potential to enhance
psychological interventions and promote adaptation to distressing experiences.
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Background
There have been dramatic advances in digital technology
over the last two decades, opening unprecedented
opportunities for developing tools to assist in mental
health care. These tools include computers, tablets,
smartphones and wearable sensors, which can provide
both accessible and cost-effective support, as well as the
potential for more reliable and effective methods of
assessment and monitoring [1]. For those with persisting
mental health problems, such as psychosis, where access
to support and self-management is often required on a
day-to-day basis, these technologies may assist in over-
coming existing barriers to effective treatment. In
addition, they are usually accessed independently and on
demand, and can therefore be empowering to users in
self-managing their own condition, a key element of per-
sonal recovery [2, 3].
Digital technologies range in their features, designs
and platforms, providing opportunities to target dif-
ferent needs associated with mental health conditions.
Smartphones in particular have become a strong focus of
digital health research due to their capabilities to provide
in-situation support in daily life through specialised appli-
cations (“apps”) [4]. Smartphone apps are a booming area
of both research and industry, with more empirical evalu-
ations needed to help refine features to minimise risks and
maximise benefits [5].
One promising use of smartphone apps is assisting
with the self-management of psychotic experiences such
as hearing voices [6–9]. These experiences, commonly
observed as persistent symptoms in psychotic disorders,
such as schizophrenia, can be distressing and impairing
[10, 11]. Psychological intervention largely involves pro-
moting the ability to adapt to and self-manage these ex-
periences in a way that reduces the impact on the
individual’s daily life [12]. Given that voices may be ex-
perienced as frequent and unpredictable, the on-demand
availability of smartphone apps suggests potential for
assisting in this active self-management when it is
needed.
Several studies have examined the use of smartphone
apps in people with persisting mental health problems,
including psychotic conditions. A recent meta-analysis
examined ownership of mobile devices and attitudes to
their use in mental health care in psychiatric patients
[13]. Across 15 studies including a total of 2129 patients
with a psychotic disorder, 66.4% of patients owned a
mobile phone, which had increased over time to 81.4%
between 2013 and 2015; furthermore, the majority of
patients reported interest in using mobile devices for
health monitoring and tracking, access to information
about their health, scheduling appointment reminders
and facilitating contact with service providers. Indeed,
recent research has shown patients are already
frequently using mobile technology for these purposes,
as well as assisting with coping with symptoms and
connecting with others [14, 15]. Initial trials have indi-
cated evidence that online and mobile technologies are
feasible and acceptable for people with psychotic disor-
ders [9, 16, 17].
One important way in which people with psychotic ex-
periences may benefit from smartphone apps is through
their ability to prompt adaptive behaviours when they
are needed in daily life. This application of mobile tech-
nology is termed “ecological momentary intervention”
(EMI [18]), involving the delivery of reminders or
prompts to users via mobile devices. EMIs have received
increased attention in recent years, with evidence for
their benefit in a variety of mental and physical health
conditions [18–23].
A related use of smartphone technology is termed
“ecological momentary assessment” (EMA [24]). EMA is
an assessment method involving the regular and
frequent self-assessment of momentary experiences in
the context of daily life. This method has been used
extensively in psychosis research as a means of recording
and examining momentary psychotic experiences and their
relationship to internal and external variables [25–27]. As
assessment is occurring repeatedly, in real time, and in nat-
ural environments, there is greater ecological validity, data
is less subject to retrospective recall bias, and it is possible
to examine the relationship between variables over time.
EMA and EMI (EMA/I) can be combined to provide
response-dependent intervention strategies via smartphone
apps in daily life.
A recent systematic review identified nine studies
with broad application of EMA/I in the assessment
and treatment of psychotic conditions, ranging from
specialised smartphone apps based on cognitive be-
havioural therapy to remote assessment of symptom
states to initiate early intervention for relapse [21].
These studies found the applications to be feasible
and acceptable for patients, and there was evidence
that they can be used to promote self-management of
symptoms and improve functioning [28, 29].
EMA/I may be particularly suited to assisting with the
self-management of voice hearing experiences, building
on prior therapeutic approaches involving enhancement
of coping strategies targeting voices and their triggers
[30]. Improving coping with voices is a key component
of cognitive behavioural therapy for psychosis [31] and
has been formally operationalised in a therapeutic
approach developed by Tarrier and colleagues [30] re-
ferred to as “Coping Strategy Enhancement” (CSE). CSE
involves an initial functional analysis of antecedents and
responses to psychotic experiences to inform the identi-
fication and implementation of coping strategies in daily
life. Research trials and case studies have shown broad
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support for CSE approaches in treating psychotic experi-
ences, although there are limited examinations of this
approach in isolation and targeting voices specifically
[30, 32–37].
EMA/I might be used to augment such coping-
focused approaches to voices in several ways. First,
EMA provides a means of capturing more reliable in-
formation about the way in which symptoms interact
and evolve over time, which has been shown to be
superior to retrospective self-report [26, 38–40]. To
aid functional analysis as the first stage of coping
interventions for voices, EMA data could be collected,
analysed and produced as in-session feedback to iden-
tify predictors of fluctuations in voices. Voice hearing
has been shown to vary depending on the individual’s
internal states (e.g. mood) and external stimuli (e.g.
social context) (see [41]). With EMA, contextual vari-
ables can be assessed alongside features of the voices
themselves, such as intensity/loudness, allowing for
the examination of within-person predictors of voice
fluctuations (e.g. [25]). Second, it is common for
psychological interventions to require clients to recall
the evolution of events, which can be challenging for
those with psychosis who tend to display cognitive
difficulties involving poor recall [42]. EMA shares
similarities to typical diary methods used in CBT for
this purpose, involving recording of information in
monitoring sheets outside of therapy to aid identification
of patterns requiring intervention and also to foster self-
awareness through self-monitoring. Electronic deliv-
ery of reminders and recording of information via
EMA could be more convenient, increase likelihood
of completion and provide more accurate and sensi-
tive information [43, 44]. Third, EMI has shown to
aid recall and promote the use of symptom self-
management strategies in psychosis [28, 45], aligning
with the primary aim of coping approaches to voices
being to improve the use of more effective coping
strategies in daily life.
To summarise, interventions which make use of specia-
lised smartphone capabilities such as EMA/I have shown
promise in assisting with management of symptoms and
improving recovery, and previous research has found
EMA/I are feasible and acceptable to people diagnosed with
a psychotic disorder. A particular application is to facilitate
self-management of persisting and distressing voices, where
EMA/I may offer a means of augmenting the effects of
these treatments to promote more consistent and adaptive
coping. Given this, the main aim of the proposed study is
to investigate the application of EMA/I in a coping-focused
intervention for voices (Smartphone Assisted coping-
focused interVention for Voices: SAVVy). This paper de-
scribes a pilot randomised controlled trial (RCT) with the
following objectives.
Objectives
There are three main objectives in this trial. The first
objective is to explore whether the intervention is feas-
ible to deliver and acceptable to participants. Feasibility
of smartphone-based EMA self-monitoring will be deter-
mined by the proportion of participants receiving the
intervention who complete at least 33% of the total
number of EMA surveys, allowing production of feed-
back in session. This cut-off was determined based on
recommendations from the EMA literature which sug-
gest that participants should complete at least 33% of
the total number of EMA surveys to provide a sufficient
number of data points for an analysis that is both reli-
able and representative of a person’s daily experience
[46]. The feasibility of the smartphone-based EMI will
also be examined through the number of EMI reminders
viewed over the course of the intervention and session
attendance rates. Acceptability will be assessed by par-
ticipant ratings of satisfactions with the intervention and
its perceived credibility prior to commencing. The sec-
ond objective is to examine the feasibility of a full-scale
trial through recruitment and attrition rates. The third
objective is to provide a preliminary estimation of the
clinical impact of this intervention alongside treatment-
as-usual (TAU) compared to TAU alone on (1) overall
severity of voices, (2) emotional and functional impact
of voices and (3) overall emotional distress. As a prelim-
inary examination of possible processes of change in
these clinical outcomes, we will also examine changes
on measures of the participant’s awareness of factors
that influence voices day-to-day and experiences of cop-
ing, as these are the primary intervention targets which
may theoretically lead to a reduction in voice severity
and impact.
Methods/design
Design
The SAVVy trial is a pilot randomised, controlled, assessor-
blinded trial, with two parallel groups, using a 1:1 allocation
ratio. Each consenting participant will be randomised to
either SAVVy + TAU or TAU alone, following the informed
consent and baseline assessment session. TAU will involve
continuation of standard treatment provided by the
usual care team (usually consisting of medication and case
management without psychological treatment). Baseline
assessments will occur pre-randomisation (T0) and at a
standard period of approximately 8 weeks following ran-
domisation (T1). All participants will be invited to
complete the outcome assessment regardless of whether
they complete the full course of intervention. Figure 1 dis-
plays the Consolidated Standards of Reporting Trials
(CONSORT) flow diagram of the study procedure. The
protocol was designed in accordance with the Standard
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Protocol Items: Recommendations for Interventional
Trials (SPIRIT) (Additional file 1) and Good Clinical
Practice guidelines.
Setting
This trial will be conducted at a specialist psychological
treatment and research clinic for people who experience
persisting and distressing voices based in Melbourne,
Australia [47]. The clinic receives referrals from across
Melbourne and surrounding areas and offers specialist
consultation and psychological interventions for auditory
hallucinations.
Participants
As this is a pilot RCT, power calculations based on effect
sizes are not appropriate to inform recruitment targets.
Rather, a sufficient sample size is needed for estimating
the standard deviation of the outcome measures to in-
form future power calculations, to determine recruit-
ment and attrition rates, and to evaluate the feasibility
and acceptability of the intervention. There is variability
across the literature regarding sample size recommenda-
tions for pilot RCTs, ranging from 24 to 70 [48–51]. We
determined a sample size of 34 (split evenly between
groups) would be sufficient to meet the aims of this
study, which is within the recommended range and in
line with pilot trials of similar interventions (e.g. [28,
52–55]).
Participants meeting the following criteria will be eli-
gible for the study: (1) over the age of 18 years; (2) suffi-
cient conversational English for meaningful participation
in the study; (3) experiencing current and persisting
auditory verbal hallucinations defined by, over the week
preceding the baseline assessment, hearing a halluci-
nated voice or voices on at least four different occasions
and/or on at least one occasion and of at least an hour’s
duration; we determined this criterion would be the
minimum frequency in order to capture their occurrence
during the EMA monitoring period; (4) experiencing
distress due to the voices (score of 1 or more on item 8
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram showing study design
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of the Psychotic Symptom Rating Scales-Auditory
Hallucinations (PSYRATS-AH [56])); (5) experiencing
voices for at least 6 months; and (6) comfortable using a
smartphone or willing to learn. Exclusion criteria are as
follows: (1) unable to provide informed consent; (2) in-
tellectual disability as assessed by the Wechsler Test of
Adult Reading (WTAR [57]) estimated IQ < 70]; (3)
voices occur solely in the context of substance or alcohol
use; (4) initiation of a new antipsychotic medication
within the previous 8 weeks; (5) too distressed or
agitated to take part in the study assessed by clinician
observation during screening or baseline assessment; (6)
current risk of harm to self or others that requires active
crisis management.
Recruitment and enrolment
Recruitment will take place at the Voices Clinic via direct
referrals to the study from relevant mental health services,
and wider advertising. All clients from the Voices Clinic
likely to meet inclusion criteria for the study will be
informed of the trial following their initial consultation ap-
pointment, alongside other treatment options.
Clients interested in taking part in the trial will then
be contacted by a member of the research team inde-
pendent from their clinical care who will explain the
study in more detail and formally screen over the phone
for eligibility. Potentially eligible and interested candi-
dates will then be sent participant information consent
forms and allowed at least 48 h to consider their partici-
pation. Those interested in participating will then be
contacted to book a time for the first assessment session,
during which eligibility is confirmed. Persons who par-
ticipate in the trial continue their routine treatment
whilst participating in the trial and are able to receive
other psychological therapies at the Voices Clinic follow-
ing the outcome assessment (or withdrawal from the
trial), irrespective of condition.
Advertising will also take place at relevant mental
health organisations and institutions, and online. Poten-
tial participants and mental health professionals will
therefore be able to contact the researchers directly if
they or a client is interested in participating in the trial.
Further, individuals who have previously taken part in
research projects at the Voices Clinic and have con-
sented to be contacted about new research opportunities
will be offered to take part.
Participants are reimbursed for time attending the two
assessment sessions and loaned a smartphone with data
allowance for the duration of the trial if they are not able
to use their own.
Allocation and blinding
Participants confirmed to be eligible following the baseline
assessment will then be subject to random allocation to
groups using minimisation procedure, conducted by an ex-
perienced researcher independent of the research team
using QMinim online software [58]. Randomisation using
minimisation will be used as it allows for better balance of
patient characteristics across groups, particularly in trials
with small sample sizes [59]. In this trial, minimisation will
balance whether voices are experienced as non-continuous
or continuous (PSYRATS-AH item 1 score ≤ 3 versus 4),
because this covariate is predicted to have an effect on
treatment response and should therefore be balanced across
groups. Allocation will occur within 2 days of the baseline
assessment. Participants will then be contacted to alert
them to their allocation, with those allocated to the treat-
ment group commencing therapy within 2 weeks of the
baseline assessment and those allocated to the control
group confirming a date for the outcome assessment.
All outcome assessments will be conducted by a re-
searcher blind to treatment allocation throughout the
study. It is not possible to blind participants to their al-
location due to the nature of the trial design. Following
allocation to the treatment or control arm, and prior to
the outcome assessment, participants will be asked not
to reveal their group allocation to the researcher con-
ducting the outcome assessment. Outside of the assess-
ments, researchers conducting the outcome assessments
are shielded from discussion of participants, and assess-
ments are conducted on different days to the therapy
sessions. In the event of an unblinding during the assess-
ment, this will be recorded and addressed by repeating
the clinical interview as soon as possible by another
blind assessor. Success of blinding will be assessed by
asking the assessor to guess which condition the partici-
pant was allocated to and indicate their confidence. The
PI (NT) is not blinded and responds to any clinical and
research issues during the trial that require knowledge
of a participant’s condition.
Materials
See Table 1 for the SPIRIT schedule of measures used in
this study. The primary outcomes will focus on feasibil-
ity and acceptability of the intervention and trial meth-
odology, with secondary outcomes evaluating clinical
measures. Trained raters will be supervised throughout
the study to ensure reliability and validity of the clinical
interviews.
Demographic variables will include gender, employment,
education, country of birth and ethnicity, in addition to
medication doses and receipt of other treatments during
enrolment. The following measures will also be used to de-
scribe the sample.
Diagnosis
Two structured clinical interviews will be used to ascer-
tain potential current diagnoses: the Mini-International
Bell et al. Trials  (2018) 19:262 Page 5 of 13
Neuropsychiatric Interview (M.I.N.I. 7.0 [60]) for DSM-5
mental disorders and the Structured Clinical Interview for
DSM-5 (SCID-5 [61]) Borderline Personality Disorder
(BPD) section only. The prevalence of voice hearing is
more common in BPD compared to other personality dis-
orders [62]; therefore, screening beyond BPD was consid-
ered unjustified given the added length of time this would
necessitate.
Cognitive ability
The Wechsler Test of Adult Reading (WTAR [57]) will be
used to estimate premorbid intellectual ability. WTAR
raw scores are standardised based on age and then con-
verted to the predicted WAIS-III IQ.
Negative symptoms
The Scale for the Assessment of Negative Symptoms (SANS
[63]) will be used to measure the severity of negative symp-
toms of psychosis at baseline. This measure has been in-
cluded as participants with greater levels of negative
symptoms may benefit less from psychological interventions
for voices [12]. The SANS is a semi-structured clinical inter-
view which assesses negative symptoms of psychosis across
five domains: affective flattening or blunting, alogia,
avolution-apathy, anhedonia-asociality, attention. Each of the
five symptoms are rated from 0 (absent) to 5 (severe) based
on responses to interview questions and observations made
by the assessor, with a total score derived from summing all
item scores. Higher scores indicate a greater severity of nega-
tive symptoms. The SANS is a very commonly used tool in
research for this purpose and has demonstrated good reli-
ability and validity [63, 64].
Internet use and familiarity
A seven-item questionnaire will be used to describe the
sample in terms of use and comfort with smartphones
and the internet in general. An example item is “How
confident are you in using applications (“apps”) on a
mobile phone?” rated on a 7-point scale from 1 (not at
all confident) to 7 (very confident).
Feasibility
Assessment of feasibility will focus on the following:
completion rates of the EMA surveys (completers de-
fined as having completed over 33% of the total number
of EMA surveys); the proportion of participants for
whom it was possible to produce EMA-based feedback
summaries; the number of EMI reminders viewed; recruit-
ment rate (number of participants referred and screened,
and proportion of eligible participants consenting to par-
ticipate) and attrition (proportion of those completing the
outcome assessment, and all four sessions of the therapy if
allocated to the treatment group); fidelity to the interven-
tion protocol (proportion of therapy checklist items en-
dorsed by therapists as completed).
Acceptability outcomes
Acceptability will be measured using a specifically de-
signed, 14-item satisfaction questionnaire. All except two
items are statements rated on a 5-point Likert scale from
1 (strongly disagree) to 5 (strongly agree). Example items
include “The coping strategy reminders were useful to
help me cope with my voices” and “It was useful to discuss
the smartphone feedback in therapy”. The item “I would
recommend this intervention to other people with voice
hearing experiences” will be the primary indicator of inter-
vention acceptability. Open-ended questions will be in-
cluded to allow participants to provide feedback according
to their own subjective experience. In addition, a sample
of approximately 12 participants who complete the inter-
vention will be invited to participate in a qualitative inter-
view, which will be reported upon separately to the main
RCT. This interview will focus on examining participants’
Table 1 SPIRIT schedule of enrolment, interventions and
assessments
Enrolment Intervention Close-out
Timepoint T0 0–8 weeks T1
Enrolment
Eligibility screen X
Informed consent X
Allocation X
Interventions
SAVVy + TAU X
TAU X
Assessments
PSYRATS-AH X X
SEPS Negative Impact X X
DASS-21 X X
4-item coping with voices X X
Receipt of other treatments X X
Medications and dosages X X
M.I.N.I. and SCID-5 BPD X
SANS X
WTAR X
Internet use and familiarity
questionnaire
X
CEQ X
Demographics X
WAI-SR X
Satisfaction questionnaire X
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experiences of different aspects of the intervention and as
a whole.
The Credibility/Expectancy Questionnaire (CEQ [65])
will be used to measure a participant’s expectations of the
likely success of the intervention and its perceived credibil-
ity prior to commencing. This measure is included based
on research emphasising participants’ perceptions of
the acceptability of the intervention prior to partici-
pating are a core element of acceptability and should
be evaluated at the feasibility and pilot phases of new
interventions [66]. The scale contains six items in
total, three referring to the credibility of the interven-
tion (factor 1) and three referring to expectations
(factor 2). The CEQ uses two rating scales, one from
1 (not at all) to 9 (very much) and another from 0%
(not at all) to 100% (very much), with higher total
scores indicating a greater expectation of positive ef-
fects of the intervention and its perceived credibility.
The questionnaire has shown good reliability and val-
idity [65]. The questionnaire will be administered im-
mediately following informed consent procedures
during the baseline assessment when the participant
will be familiar with the details of the intervention.
The Working Alliance Inventory – Short Revised
(WAI-SR [67]) will also be administered to participants
in the intervention arm at the end of the final session to
provide data on the therapeutic alliance with the therap-
ist. This is a widely used measure of therapeutic alliance
between client and practitioner, which corresponds to
the extent to which the participant perceives successful
alignment on the goals and tasks of therapy, and the
accompanying therapeutic bond. The scale contains 12
items covering subscales of goals, tasks and bond
between client and therapist, scored on a 5-point
scale from 1(seldom) to 5(always), with some reverse-
rated items.
Clinical outcomes
The following clinical measures will be evaluated as sec-
ondary outcomes in this trial to provide a preliminary
estimate of efficacy. All measures will request ratings
relevant to the past week.
Overall severity of voices
The PSYRATS-AH [56] total score will be the pri-
mary clinical outcome measure for this trial, reflect-
ing changes in voice phenomenology, severity and
impact. The measure is a structured interview exam-
ining 11 dimensions of auditory hallucinations, each
rated on a 5-point ordinal scale with total scores
summed, with higher scores representing greater
overall severity of voice hearing experiences. The
scale has demonstrated good reliability and validity
with sensitivity to change [56, 68].
Negative impact of voices
The Subjective Experiences of Psychosis Scale –
Negative Impact Subscale (SEPS [69]) will be used to
evaluate the negative emotional and functional im-
pact of the voices on the person. The SEPS is a 45-
item self-report scale consisting of three subscales
assessing experiences of psychosis. In this case, par-
ticipants will be asked to select “voices” as the
psychotic experience they are rating. The total score
of subscale 1 “negative impacts of experiences” (29
items) will be used in the current study. Items are
rated on a 5-point scale from 1 (not at all) to 5
(very much), with scores summed to produce an
overall score, with higher scores representing a
greater negative impact of the voices on the person.
The SEPS has demonstrated good to excellent reli-
ability and validity [69].
Emotional distress
The Depression, Anxiety and Stress Scale-21 (DASS-21
[70]) scale is a commonly used measure of depression,
anxiety and stress. Each of the 21 items is rated on a
4-point scale from 0 (did not apply to me at all) to 3
(applied to me very much, or most of the time). Sub-
scale scores are totalled and then doubled to yield an
overall score, with higher scores indicating a greater
level of overall emotional distress. The scale has dem-
onstrated good reliability and validity in clinical sam-
ples [71].
Process measures
Although the sample size and design preclude mediation
analysis, we are including several possible process mea-
sures in this trial to evaluate their sensitivity to change.
These include two single items using a 0–100-mm visual
analogue scale (VAS) measuring confidence in coping
with the voices and awareness of factors influencing
their fluctuations, and two multiple choice items meas-
uring the range of helpful coping strategies and the
consistency of their use. These items reflect the primary
intervention aims which may theoretically account for
reductions in voice severity and impact.
 “How confident are you in your ability to cope with
the voice/s day to day?”, VAS anchored 0 mm (not
at all confident) to 100 mm (very confident)
 “I am aware of things which make the voice/s more
or less intense”, VAS anchored 0 mm (not at all) to
100 mm (very much)
 “Over the past week, how often have you used
coping strategies for the voice/s?”, multiple choice: 1
(never when I heard voice/s); 2 (a few of the times I
heard voice/s); 3 (about half of the times I heard
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voice/s); 4 (most times I heard voice/s); 5 (every time
I heard voice/s)
 “How many helpful coping strategies do you have
to manage the voice/s?”, multiple choice: 1 (I
don’t have any helpful coping strategies for the
voice/s); 2 (I have one or two helpful coping
strategies for the voice/s); 3 (I have a few different
helpful coping strategies for the voice/s); 4 (I have
several helpful coping strategies for the voice/s); 5
(I have a lot of helpful coping strategies for the
voice/s)
Planned intervention
Participants allocated to the therapy group will re-
ceive four face-to-face sessions of approximately 1 h
in length, over the 8-week period between baseline
and outcome assessments. Sessions are spaced ap-
proximately 1–2 weeks apart. In addition, these par-
ticipants will use a smartphone app between sessions
(described below), either their own or one provided
to them for the duration of the trial. A breakdown
of the intervention details and sequence are provided in
Fig. 2, both within and between sessions. The intervention
is manualised and will be delivered by the trial coordinator
(IB), a trainee psychologist undertaking doctoral studies in
clinical psychology, with regular supervision by the PI
(NT).
This intervention has been informed by the frame-
work of coping strategy enhancement (CSE [30, 72]
and literature on antecedents and coping with voices
(e.g. [41, 73–77]). CSE has recently been applied in a
brief format targeting distressing voices specifically,
supporting feasibility, acceptability and preliminary
evidence for improved clinical outcomes [37]. A panel
of four individuals with lived experience of voice
hearing based in Sussex, UK, were also consulted in
the early stages of this research to provide feedback
on the design of the intervention and trial, including
the wording and schedule of EMA/I surveys.
As an initial phase of the intervention across the
first and second sessions, functional analysis will be
used to formulate patterns in voice activity, focusing
on identifying the antecedents and responses which
may give insight into how voices are being main-
tained. Building from this understanding, the remain-
der of the intervention will focus on identifying and
implementing alternative responses to the voices and
their antecedents which may disrupt problematic main-
tenance cycles associated voice activity and related
distress. The therapy can therefore be conceptualised as
having two sequential stages: the first involving information
Fig. 2 Intervention overview
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gathering and building understanding of daily patterns in
voices through functional analysis, and the second involv-
ing identification and implementation of individualised
coping responses to voices based on the functional analysis.
Across these phases, EMA/I will be used to enhance the
core aims of the intervention.
Stage 1: functional analysis and ecological momentary
assessment
Following the first session, participants will complete
a 6-day EMA monitoring period during which they
complete 10 EMA surveys per day, occurring at semi-
random intervals within an individualised 12-h waking
period. Each EMA survey will be identical and
contain 39 items measuring common antecedents and
responses to voices, in addition to voice intensity,
distress and impact. A full list of these items and in-
structions is provided in Additional file 2. The devel-
opment of the EMA schedule and items involved
several iterative stages, including comprehensive lit-
erature reviews, consultations with expert clinicians,
researchers and lived experience consultants, piloting
by researchers, and a small pilot of the intervention
with three participants to refine protocols and
confirm acceptability of the EMA/I procedure. The
purpose of this EMA monitoring period is to provide
data which can be analysed to identify potential
predictors of voice intensity. In line with recommen-
dations in the literature, at least 33% of the total
number of EMA surveys will need to have been com-
pleted by the participant in order for analysis of feed-
back to be conducted [46]. Analysis of the EMA data
(produced for the purpose of feedback) will include
within-person summary statistics and exploratory
multiple regressions conducted on Stata Statistical
Software [78], allowing identification of items which
predict the intensity of voices. Variables with a stan-
dardised beta co-efficient of greater than 0.3 were
considered to justify the provision of feedback.
If possible, a feedback sheet will be provided to partici-
pants in the second session which will contain the fol-
lowing information: (a) the number of survey responses
entered during the monitoring period; (b) average voice
intensity and distress scores over the monitoring period;
(c) situations, triggers and responses which predicted in-
creased or decreased voice intensity according to mul-
tiple regression analysis; and (d) a list of the specific
responses to voices reported over the monitoring period
and their average reported helpfulness. This feedback
will be framed as a guide due to potential limitations in
capturing sufficient voice hearing occasions to detect
predictors and to avoid inferring causation from correl-
ation data. The feedback will be discussed in the session
alongside patterns noticed by the participant during the
EMA monitoring period, with the aim of building a
functional analysis of voice activity.
Stage 2: identification and implementation of coping
strategies and ecological momentary intervention
Based on the functional analysis conducted across ses-
sions 1 and 2, the therapist and participant will work
collaboratively to identify potential coping strategies
which may assist the person to cope with their voices
and potentially modify patterns in voice activity. To-
wards the end of the second session, coping strategies
will then be chosen by the participant and then coded
into the app as personalised coping statements (e.g. “Lis-
ten to some relaxing music”). Then, for 10 days follow-
ing the second session, participants will be sent EMI
prompts via the smartphone app of their personalised
coping statements. These reminders will occur five times
per day, presented semi-randomly within their waking
hours. Participants will also be able to view them on de-
mand by pressing a button within the app. In addition,
participants will complete a short survey each evening
asking them about their experiences using the app, the
helpfulness of their coping strategies and potential bar-
riers to coping. The latter information is then sum-
marised as feedback and provided to the participant in
the following session if possible, with the aim of tracking
progress. Based on this discussion, there will be an op-
tion to create new coping statements following session 3
or keep the same for a second, identical EMI period.
The fourth session will similarly involve reviewing pro-
gress and discussing feedback from the app if available,
ending with a discussion of how to maintain gains fol-
lowing the end of the intervention.
Fidelity to the intervention protocol will be supported
through (a) use of an intervention manual clearly detail-
ing the protocol for each session and procedures be-
tween sessions; (b) provision of a participant guide for
use during the session which can be used to structure
the content and record information; (c) regular supervi-
sion of the therapist by the PI, who has expertise in both
interventions for voices and the use of digital interven-
tions; and (d) completion of a fidelity checklist following
each session by the therapist to record key components
of the session.
Smartphone application
The movisensXS [79] app will be used to facilitate
EMA/I in the current study. This app connects with a
Web-based platform that allows researchers to program
simple and secure EMA/I surveys or prompts that can
be individualised for each participant, and download
data remotely. The app is downloaded onto the smart-
phone at the end of the first session, with a schedule of
EMA surveys pre-programmed to commence on the
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following day. At the end of each subsequent session,
the app is updated (via the Web-based platform) with
the participant’s coping strategy reminders, which com-
mence the following day. Use of this survey format was
tested by three individuals with persisting voices prior,
providing a basis for evaluating the procedures and re-
fining the EMA/I content and design prior to the com-
mencement of the study. Piloting of the movisensXS app
was also conducted by the researchers over 7 days to en-
sure it is reliable for the study purposes.
Planned analysis
Feasibility of the intervention will be reported as
descriptive statistics, focusing on the proportion of
participants completing at least 33% of the total num-
ber of EMA surveys, the proportion of those in which
feedback summaries were able to be produced, and
the proportion of EMI reminders viewed. Acceptabil-
ity will be summarised as means and standard devia-
tions of responses to each item within the satisfaction
questionnaire, the proportion of participants giving
favourable responses, and representative samples of
feedback from open-ended questions. The mean and
standard deviation of total scores of the CEQ will
also be reported. Feasibility of the trial will be re-
ported descriptively and in figures of referral, screen-
ing, consent and attrition, as well as the proportion
of fidelity checklist items endorsed as completed.
Clinical outcomes will be analysed on an intention-to-
treat basis using all available data, adopting statistical
approaches to managing missing data if appropriate
to the dataset. Results will be summarised as means
and/or medians (as appropriate), standard deviations
and ranges of all outcome and process measures at
T0 and T1 for both groups. Analysis of covariance
will be used to estimate T1 between-group differences
on all outcome and process measures, controlling for
baseline scores. Presentation of the analysis will focus
on point estimates and associated 95% confidence in-
tervals rather than statistical significance (p values).
Standardised effect sizes will be derived using Cohen’s
d. Secondary analyses will include per-protocol ana-
lyses (including only participants who attended at
least 50% of therapy sessions) and analyses controlling
for baseline moderator variables.
Data monitoring and management
Assessment and therapy data
Training on the administration and scoring of assess-
ments will be provided to all researchers conducting as-
sessments, as well as relevant ethics procedures and
protocols for managing and storing data. Regular super-
vision will also be provided with a continual focus on as-
sessments and data management. Data collected during
assessments will be recorded on paper case report forms
(CRFs) and securely stored. Data will be extracted to a
secure data file by a researcher blind to participant
group allocation. For each stage of data cleaning and
analysis that is performed, a separate time-stamped
computer file will be created and saved within an orga-
nised file system. Research data held electronically will
be backed up regularly and stored on secure networks.
To aid data quality, checks will include examination of
recorded data for out-of-range values and examination
of a random sample of CRFs by a second researcher to
identify potential data entry errors. Files containing
treatment information will be kept in a separate location
to the assessment files to prevent unblinding and will be
extracted to separate electronic data files not accessible
to blinded researchers. A formal data monitoring com-
mittee is not required by local ethics guidelines for a
trial of this type, and no interim analysis is anticipated.
Smartphone app data
The movisensXS [79] smartphone app used in the
current study is an existing research and clinical tool.
The app has been used extensively in EMA research and
has been designed to be fully compliant with relevant
Australian data protection and health records legislation.
No personal identifying information is ever collected
within the app. Surveys completed within the app
throughout the duration of the treatment are sent via
encrypted transfer to a secure online server accessible
only by the research team using a secure, registered,
password-protected account. The login details will only
be known to members of the research team. Data is
downloaded and saved in a re-identifiable Excel spread-
sheet format, which is then password protected and
stored securely.
Research governance and ethics
The trial is administered by Swinburne University of
Technology. This study has been approved by Alfred
Hospital Ethics Committee (project 440/16) and Swinburne
University Human Research Ethics Committee (project
2016/285). It is conducted in accordance with the Declar-
ation of Helsinki, Good Clinical Practice guidelines and the
Australian National Statement on Ethical Conduct in
Human Research [80]. Researchers obtain full informed
consent from all participants prior to completing the base-
line assessment. A copy of the consent form can be
requested by contacting the corresponding author. There
are no restrictions on reporting findings of this trial, which
will be published in full in the peer-reviewed literature.
Major protocol amendments will be submitted to ethics
committees and detailed in the trial registry and trial
protocol if necessary.
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Serious adverse events
Serious adverse events will be monitored and re-
corded for all enrolled participants throughout the
running of the trial. In line with the National State-
ment on Ethical Conduct in Human Research [80], in
the context of this trial, serious adverse events in-
clude events that lead to participant death, or that
are life-threatening, require inpatient hospitalisation,
or result in persistent or significant disability/incap-
acity. Any such events will be recorded and reviewed
with the PI to determine the likelihood of any rela-
tionship to the intervention, with action taken as
appropriate and notification to the approving Ethics
Committees.
Discussion
The use of digital technology for promoting mental
health self-management is becoming a prominent area
of research. Smartphone-based ecological momentary
assessment and intervention (EMA/I [18, 24]) are par-
ticularly promising given their ability to provide mo-
mentary assessment of relevant clinical processes and
promote adaptive responses to symptoms in daily life.
Few research trials have investigated the clinical utility
of EMA/I in the form of specialised smartphone apps or
mobile devices; however, the existing literature high-
lights the promise of this technology for promoting self-
management of mental health [18–21, 81].
In the context of those with distressing voice hearing
experiences, the use of smartphone-based EMA/I may
build on existing therapeutic approaches to improving
coping with voices. EMA/I may provide important link-
ages between traditional face-to-face therapy and daily
life not only to establish more consistent application of
coping strategies discussed in sessions, but also to cap-
ture important information often lost in the complexity
of daily life. The proposed study is an investigation of
such capabilities through evaluation of the feasibility, ac-
ceptability and preliminary clinical outcomes of a novel
intervention involving smartphone-based EMA/I to im-
prove coping with distressing voices.
There are currently strikingly few empirical evalua-
tions of smartphone apps for mental health [4]. This is
problematic given the number of apps readily available
for use by consumers, without sufficient understanding
of their potentially harmful effects. From another angle,
it is critical to understand how these technologies should
be designed to maximise their benefits and use across
different contexts. The current study aims to evaluate
EMA/I as specific smartphone technologies for promot-
ing adaptation to distressing psychotic experiences. The
focus on voice hearing experiences was chosen given the
logical mapping of EMA/I onto existing therapeutic ap-
proaches to coping with voices; however, we hope these
findings will provide insights into the use of EMA/I in
clinical practice with broader clinical implications.
Trial status
The trial commenced recruitment with the first partici-
pant allocated in March 2017. It is anticipated that the
trial will cease recruitment in early to mid-2018.
Additional files
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 101 kb)
Additional file 2: Smartphone-based EMA and EMI items. (DOCX 26 kb)
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